Acute Respiratory Infection
Conditions
Keywords
ultrafiltered red ginseng, hydrolyzed ginseng, acute respiratory illness, clinical trial
Brief summary
This study was conducted to investigate the effects of daily supplementation of GS-3K8 or GINst15 on acute respiratory illness (ARI) in healthy subjects.
Detailed description
This study was a 8 weeks, randomized, double-blind, placebo-controlled trial. Forty five subjects were randomly divided into GS-3K8 (Ultrafiltered red ginseng extract) or GINst15 (Hydrolyzed ginseng extract) or placebo group. The primary clinical outcome measure was the incidence of ARI. The secondary clinical outcome measure was the development and duration of ARI symptoms.
Interventions
DIETARY_SUPPLEMENTGS-3K8
GS-3K8 (ultrafiltered red ginseng extract) 1 g/day
DIETARY_SUPPLEMENTGINst15
GINst15 (hydrolyzed ginseng extract) 1 g/day
DIETARY_SUPPLEMENTPlacebo
Placebo 1 g/day
Sponsors
Chonbuk National University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
39 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Age 39-65 years with healthy adults
Exclusion criteria
* Subjects had been vaccinated against influenza in the previous 6 months * Subjects with symptoms of upper respiratory tract infection * Subjects with acute/chronic disease * History of alcohol or substance abuse * History of disease that could interfere with the test products or impede their absorption * Subjects taking medications such as immune or upper respiratory tract infection related drug or functional foods * Abnormal liver or kidney function tests * Pregnant or lactating women and heavy smokers * Being judged by the responsible physician of the local study center as unfit to participate in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence rate of ARI (by questionnaire) | 18 weeks (intervention for 12 weeks, follow up for 6 weeks after termination) | Incidence of ARI were assessed before and after intervention and followed up for 6 weeks after termination. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Development of ARI symptoms (by questionnaire) | 18 weeks (intervention for 12 weeks, follow up for 6 weeks after termination) | Development of ARI symptoms (score) were assessed before and after intervention and followed up for 6 weeks after termination. |
| Duration of ARI symptoms (by questionnaire) | 18 weeks (intervention for 12 weeks, follow up for 6 weeks after termination) | Duration of ARI symptoms were assessed before and after intervention |
Countries
South Korea
Outcome results
None listed